Molecular breast imaging (MBI) developer Dilon Diagnostics said a patient has won a legal battle to obtain health insurance coverage of her MBI study.
Karen Larson of Golden Valley, MN, had her breast cancer detected using Dilon's MBI technology. However, her new insurance plan considered the procedure investigative and elected not to cover a subsequent study recommended as part of her follow-up, Dilon said. Larson appealed her case to the Office of Medicare Hearings and Appeals, which overturned the health insurance denial.
In the ruling, the judge said that the MBI study was not investigational and, therefore, it was medically necessary for Larson. The ruling was forwarded to her medical insurance provider, requesting immediate coverage of her procedure, Dilon said.
